Forum Agenda

July 22, 14:00–17:30

The Booming Radiopharmaceuticals Session

Stay tuned

planner
Tao Xu:Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd


14:00-14:05 Moderator
Yumin Zhang :Founder, Anchoray Inc; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)


14:05-14:10 Opening Remarks
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd


14:10-14:30 Innovative Design of Radiopharmaceuticals
Zhen Cheng:Director, Molecular Imaging Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society of Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry, and International Association of Advanced Materials


14:30-14:45 Clinical Development Strategies of Radiotherapeutic Drugs in Tumor Therapy
Gloria Gong:CEO, Foresight Pharma Consulting; Advisor for Bain & Company


14:54-15:00 Integrating RDC and ADC Theranostics for Improving Oncology Standard of Care
Zhican Qu:Chairman and CSO, Nanolattix  Biotech


15:00-15:20 Rest Break


15:20-16:00 Panel. Discussion 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu(Moderator):Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li:Partner, StarsCapital
Chunguang Liu:Managing Partner, Tailong VC
Feng Yu:Founder & CEO, ELI Radiopharma    
Xun Zhu:Honorary Director-General, Tonacea New Drug Talent Club


16:00-16:40 Panel. Discussion 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li (Moderator):Secretary and Deputy Director, Institute of Radiation Medicine, China Institute for Radiation Protection (CIRP)
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd
Jim Cai:Chairman & CEO, New RadiomedicineTechnology
Bo Shan:CEO, BoomRay Pharmaceuticals
Greg Chen:Founder & CEO, RadAlliance Therapeutics.
Xiang S Ye:CEO & CSO, AlphaGen Therapeutics
Heyun Chao:Senior Vice President, C Ray Therapeutics


16:40-17:30 Panel. Discussion 3:What Big Pharma Seeks in Radiopharmaceuticals?
Xiang Li (Moderator):Global Partner of Fosun; Senior Vice President, Fosun Pharma; Co-President & Chief Scientific Officer, Innovative Drug Division; CEO, Fosun New DrugsWuzhou Wan:President, Central Research Institute, Yunnan Baiyao Group
Fred Li:Director, Search & Evaluation, Novartis China
Duan Wang Dr.:Scientific Licensing Director,  Collaborate to Cure China, Bayer Pharmaceuticals
Peng Yu:Clinical lead, Radiopharmaceutical R&D, AstraZeneca